Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

Funding

Conflict of interest: Dr A.N. reports grants and personal fees from Boehringer Ingelheim, personal fees from Novo Nordisk, out side the submitted work. Dr J.T. has nothing to disclose. Dr L.K. has nothing to disclose. Dr C.H.S. reports personal fees from Astra Zeneca, personal fees from Boehringer Ingelheim, personal fees from Eli Lilly, personal fees from Genericon, personal fees from Merck, personal fees from MSD, personal fees from Novo Nordisc, personal fees from Pfizer, personal fees from Sanofi Aventis, personal fees from Takeda, during the conduct of the study. Dr T.A.S. holds Novo Nordisk stock. Dr G.S. reports grants from MSD Italia, grants from Heart and Lung Foundation, grants from Italian Society of Cardiology, outside the submitted work. Dr S.W. reports personal fees from Boehringer Ingelheim, personal fees from Pfizer, personal fees from Bristol Myers Squibb, personal fees from Merck Sharp & Dohme, personal fees from Novartis, personal fees from Astra Zeneca, out side the submitted work. Dr G.R. has nothing to disclose. Dr C.C. has nothing to disclose. Dr C.T P. reports grants and personal fees from Bayer, grants from Biotronics, outside the submitted work. Dr K.K. has nothing to disclose. Dr J.C.K. has nothing to disclose. Dr S.A. has nothing to disclose. Dr T.W. reports grants and personal fees from Tarix Pharmaceutical, outside the submitted work. Dr H.D. has nothing to disclose. Dr B.S.L. reports grants and personal fees from AstraZeneca, grants from Pfizer, outside the submitted work.